Having trouble accessing articles? Reset your cache.

XenoPort up on Phase I data for potential autoimmune therapy

XenoPort Inc. (NASDAQ:XNPT) gained $1.71 (15%) to $12.86 on Friday after reporting

Read the full 127 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE